GB201719169D0 - Novel T-cell receptor and ligand - Google Patents

Novel T-cell receptor and ligand

Info

Publication number
GB201719169D0
GB201719169D0 GBGB1719169.3A GB201719169A GB201719169D0 GB 201719169 D0 GB201719169 D0 GB 201719169D0 GB 201719169 A GB201719169 A GB 201719169A GB 201719169 D0 GB201719169 D0 GB 201719169D0
Authority
GB
United Kingdom
Prior art keywords
ligand
novel
cell receptor
receptor
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1719169.3A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University College Cardiff Consultants Ltd
Original Assignee
University College Cardiff Consultants Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University College Cardiff Consultants Ltd filed Critical University College Cardiff Consultants Ltd
Priority to GBGB1719169.3A priority Critical patent/GB201719169D0/en
Publication of GB201719169D0 publication Critical patent/GB201719169D0/en
Priority to EP18808079.0A priority patent/EP3713954A1/en
Priority to CA3079156A priority patent/CA3079156A1/en
Priority to KR1020207014073A priority patent/KR20200085776A/ko
Priority to AU2018369698A priority patent/AU2018369698A1/en
Priority to JP2020544990A priority patent/JP2021505190A/ja
Priority to MX2020005200A priority patent/MX2020005200A/es
Priority to PCT/GB2018/053321 priority patent/WO2019097244A1/en
Priority to EA202091276A priority patent/EA202091276A1/ru
Priority to BR112020007469-1A priority patent/BR112020007469A2/pt
Priority to SG11202002993UA priority patent/SG11202002993UA/en
Priority to CN201880074771.1A priority patent/CN111372944A/zh
Priority to ZA2020/02417A priority patent/ZA202002417B/en
Priority to IL274482A priority patent/IL274482A/en
Priority to US16/877,928 priority patent/US11850264B2/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Hematology (AREA)
GBGB1719169.3A 2017-11-20 2017-11-20 Novel T-cell receptor and ligand Ceased GB201719169D0 (en)

Priority Applications (15)

Application Number Priority Date Filing Date Title
GBGB1719169.3A GB201719169D0 (en) 2017-11-20 2017-11-20 Novel T-cell receptor and ligand
CN201880074771.1A CN111372944A (zh) 2017-11-20 2018-11-16 新型γδT细胞受体和其配体
MX2020005200A MX2020005200A (es) 2017-11-20 2018-11-16 Novedoso receptor de celulas t gamma delta y su ligando.
EA202091276A EA202091276A1 (ru) 2017-11-20 2018-11-16 Новый гамма дельта т-клеточный рецептор и его лиганд
KR1020207014073A KR20200085776A (ko) 2017-11-20 2018-11-16 신규한 감마 델타 t-세포 수용체 및 이의 리간드
AU2018369698A AU2018369698A1 (en) 2017-11-20 2018-11-16 Novel gamma delta T-cell receptor and its ligand
JP2020544990A JP2021505190A (ja) 2017-11-20 2018-11-16 新規γδ Ｔ細胞受容体及びそのリガンド
EP18808079.0A EP3713954A1 (en) 2017-11-20 2018-11-16 Novel gamma delta t-cell receptor and its ligand
PCT/GB2018/053321 WO2019097244A1 (en) 2017-11-20 2018-11-16 Novel gamma delta t-cell receptor and its ligand
CA3079156A CA3079156A1 (en) 2017-11-20 2018-11-16 Novel gamma delta t-cell receptor and its ligand
BR112020007469-1A BR112020007469A2 (pt) 2017-11-20 2018-11-16 receptor de células t e ligante
SG11202002993UA SG11202002993UA (en) 2017-11-20 2018-11-16 Novel gamma delta t-cell receptor and its ligand
ZA2020/02417A ZA202002417B (en) 2017-11-20 2020-05-04 Novel gamma delta t-cell receptor and its ligand
IL274482A IL274482A (en) 2017-11-20 2020-05-06 A novel T-cell receptor gamma delta and its ligand
US16/877,928 US11850264B2 (en) 2017-11-20 2020-05-19 Gamma delta T-cell receptor and its ligand

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1719169.3A GB201719169D0 (en) 2017-11-20 2017-11-20 Novel T-cell receptor and ligand

Publications (1)

Publication Number Publication Date
GB201719169D0 true GB201719169D0 (en) 2018-01-03

Family

ID=60805814

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1719169.3A Ceased GB201719169D0 (en) 2017-11-20 2017-11-20 Novel T-cell receptor and ligand

Country Status (15)

Country Link
US (1) US11850264B2 (https=)
EP (1) EP3713954A1 (https=)
JP (1) JP2021505190A (https=)
KR (1) KR20200085776A (https=)
CN (1) CN111372944A (https=)
AU (1) AU2018369698A1 (https=)
BR (1) BR112020007469A2 (https=)
CA (1) CA3079156A1 (https=)
EA (1) EA202091276A1 (https=)
GB (1) GB201719169D0 (https=)
IL (1) IL274482A (https=)
MX (1) MX2020005200A (https=)
SG (1) SG11202002993UA (https=)
WO (1) WO2019097244A1 (https=)
ZA (1) ZA202002417B (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230226183A1 (en) * 2020-01-15 2023-07-20 The Regents Of The University Of California Compositions and methods for altering gamma delta t cell activity
EP4059955A1 (en) 2021-03-19 2022-09-21 Medizinische Hochschule Hannover Hla-dr-specific gamma delta tcr constructs and use thereof
EP4472742A1 (en) 2022-02-03 2024-12-11 University College Cardiff Consultants Limited Novel t-cell receptor
US20240043496A1 (en) * 2022-07-26 2024-02-08 Gadeta B.V. Delta t-cell or gamma receptor chains or parts thereof for treating ovarian cancer

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5260223A (en) * 1986-07-03 1993-11-09 President & Fellows Of Harvard College Methods for detection of human gamma, γ T cell receptor
WO1996013593A2 (en) * 1994-10-26 1996-05-09 Procept, Inc. Soluble single chain t cell receptors
WO1999060120A2 (en) 1998-05-19 1999-11-25 Avidex Limited Soluble t cell receptor
AU2002308481A1 (en) * 2001-05-01 2002-11-11 Senomyx, Inc. High throughput cell-based assay for monitoring sodium channel activity and discovery of salty taste modulating compounds
AU2002359666A1 (en) * 2001-12-10 2003-06-23 California Institute Of Technology Method for the generation of antigen-specific lymphocytes
CN1842709A (zh) * 2003-07-10 2006-10-04 塞诺米克斯公司 使用表达人的ENaC的卵母细胞的改进的电生理测定法和用于在使用膜电位报告染料的测定中提高ENaC增强子功效的PHENAMIL的用途
WO2013155406A1 (en) * 2012-04-12 2013-10-17 The Chinese University Of Hong Kong Contragestion and treating inflammation by modulating sodium channel activity in the epithelium
WO2015121454A1 (en) * 2014-02-14 2015-08-20 Cellectis Cells for immunotherapy engineered for targeting antigen present both on immune cells and pathological cells
PL3119807T3 (pl) * 2014-03-19 2019-09-30 Cellectis Specyficzne wobec cd123 chimeryczne receptory antygenowe do immunoterapii nowotworów
MX2016014434A (es) 2014-05-13 2017-02-23 Chugai Pharmaceutical Co Ltd Molecula de union a antigeno redirigida a celulas t para celulas que tienen funcion de inmunosupresion.
WO2016016344A1 (en) 2014-07-29 2016-02-04 Cellectis Ror1(ntrkr1)specific chimeric antigen receptors for cancer immunotherapy
DK3271382T3 (da) * 2015-03-16 2020-05-04 Max Delbrueck Centrum Fuer Molekulare Medizin Helmholtz Gemeinschaft Fremgangsmåde til detektion af nye immunogene T-celleepitoper og isolering af nye antigenspecifikke T-cellereceptorer ved hjælp af et MHC-cellebibliotek

Also Published As

Publication number Publication date
ZA202002417B (en) 2021-07-28
US11850264B2 (en) 2023-12-26
US20200316124A1 (en) 2020-10-08
CA3079156A1 (en) 2019-05-23
AU2018369698A1 (en) 2020-04-30
MX2020005200A (es) 2020-08-20
JP2021505190A (ja) 2021-02-18
SG11202002993UA (en) 2020-06-29
BR112020007469A2 (pt) 2020-11-03
EA202091276A1 (ru) 2020-09-04
WO2019097244A1 (en) 2019-05-23
IL274482A (en) 2020-06-30
EP3713954A1 (en) 2020-09-30
KR20200085776A (ko) 2020-07-15
CN111372944A (zh) 2020-07-03

Similar Documents

Publication Publication Date Title
IL274025A (en) A new T-cell receptor
ZA202003472B (en) Psma ligands for imaging and endoradiotherapy
ZA202002966B (en) T-cell receptor (tcr)-binding antibodies and uses thereof
SG11202103609YA (en) T-cell receptors and uses thereof
IL286107A (en) Spiro-lactam nmda receptor modulators and uses thereof
IL264514A (en) Spiro-lactam modulates and uses of the nmda receptor
IL264488A (en) Spiro-lactam nmda receptor modulators and uses thereof
IL247873A0 (en) Peptides and antibodies derived from the cdr3 region of the t-cell receptor
GB201520191D0 (en) T-cell receptor and uses thereof
GB201702617D0 (en) Receptor
PL3512537T3 (pl) Immunoterapia limfocytami t
PL3420150T3 (pl) Urządzenie sitowe
IL274482A (en) A novel T-cell receptor gamma delta and its ligand
HUE056092T2 (hu) Gyógyszerkeverõ eszköz
GB201705960D0 (en) Novel ligand and use thereof
GB201710450D0 (en) Device
IL271385A (en) Install a cell seal
GB2577816B (en) Device
HK40036653A (en) Novel gamma delta t-cell receptor and its ligand
ZA201806585B (en) Dredging device
GB201719948D0 (en) Ring binders/tramperline binders any size and any size extra
GB201701887D0 (en) Receptor
GB201700926D0 (en) Receptor
GB201706266D0 (en) Intrinsically safe screen means
GB201701585D0 (en) Support device

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)